Alcresta has fueled up with venture dollars en route to commercialization of its biotech-inspired nutritional products with a $10 million Series A round from previous backers Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.
Life science stocks are hot, venture capitalists have renewed their interest in biotech and a host of big companies are on the hunt for startup vaccine makers with novel products and technology. Medicago is the latest developmental vaccine maker to attract a bid.
Sanofi's closure of a major U.K. facility marks another setback for life sciences employment in the country, and there are no guarantees that workers can find jobs at the new companies that could inhabit the facilities of their former employers.
With an experimental therapy that could save "millions of lives," biotech startup XO1 Ltd. said it has raised $11 million in a Series A round of financing from Index Ventures.
In a piece for Nature Biotechnology, serial biotech entrepreneur and MIT professor Robert Langer shared some of his experiences in launching more than two dozen biotechs over the past 26 years.
Calling everyone from the global biotech community. We've begun seeking nominations for FierceBiotech 's 2013 class of Fierce 15 companies, and our editors would like to give readers a voice in the selection process. It's really easy: Just fill out our online nomination form here.
Effector Therapeutics has rallied marquee investors for a sizable $45 million Series A financing, determined to use discoveries in protein translation to mine for new cancer drugs.
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>
A little more than a year ago, the startup crew at Lumena Pharmaceuticals was based in North Carolina and working on a new drug for diabetics. But things have changed. The company moved to San Diego, refocused its lead program on a rare liver disease and today announced that it had rounded up $23 million in Series A cash from a trio of venture groups.